Dwarkesh Pharmaceuticals Private Limited
GIDC Vatwa, Ahmedabad, Gujarat
SEND SMS
SEND EMAIL
Product Details:
| Minimum Order Quantity | 100000 Box |
| Pac k Size | 10 x 10 Tablets |
| Grade standard | Medicine Grade |
| Packaging Type | Strips |
| Type of Medicines | Allopathic |
| Form Of Medicines | Tablets |
Additional Information:
Additional Information:
| Each 5 ml contains :- | |
| Diastase (1 : 1200) I.P. | 50 mg. |
| Pepsin (1 : 3000) I.P. | 10 mg |
| Flavoured Syrup base | Q.S. |
Additional Information:
TYPICAL USAGE:Adjunctive treatment of endometrial carcinoma, adjunctive treatment of renal carcinoma, breast cancer, contraception, uterine bleeding, endometrial cancer, endometriosis, mild to moderate endometriosis, progestogenic opposition of oestrogen hrt.
MECHANISM OF ACTION:Progestins diffuse freely into target cells in female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.Additional Information:
Additional Information:
Additional Information:
Additional Information:
Additional Information:
TYPICAL USAGE: Primary treatment of pulmonary and extrapulmonary.
MECHANISM OF ACTION: Ethambutol inhibits arabinosyl transferases which is involved in cell wall biosynthesis. By inhibiting this enzyme, the bacterial cell wall complex production is inhibited. This leads to an increase in cell wall permeability.
Additional Information:
Additional Information:
MECHANISM OF ACTION: Danazol suppresses the pituitary-ovarian axis by reducing the release of follicle-stimulating hormone and luteinizing hormone. This causes the regression and atrophy of endometrial tissue, decreases growth rate of abnormal breast tissue and reduces attacks in hereditary angioedema.
Additional Information:
Product Details:
| Usage | Hospital, Clinical |
| Product Type | Finished Product |
| Dosage Form (If Applicable) | Tablets |
Typical Usage: Benign gastric and peptic ulcer. Erosive of ulcerative gastro-oesophageal reflux disease (GORD). Acid peptic disease.
Mechanism Of Action: Rabeprazole is an oral drug that is used for the treatment of conditions caused by acid. It is in a class of drugs called proton pump inhibitors or PPIs which block the production of acid by the stomach. Other drugs in the same class include lansoprazole (Prevacid),omeprazole (Prilosec), pantoprazole (Protonix), esomeprazole , and dexlansoprazole (Dexilant). PPIs are used for the treatment of acid-caused conditions such as stomach and duodenal ulcers, gastroesophageal reflux disease (GERD) and Zollinger-Ellison Syndrome. Rabeprazole, like other PPIs, blocks the pump in the wall of the stomach that secretes acid into the stomach.By blocking the pump, the secretion of acid into the stomach is decreased, and this allows ulcers in the stomach and esophagus to heal. The FDA approved rabeprazole in August 1999.
Additional Information:
| Each Uncoated Tablet contains :- | |
| Aceclofenac | 100 mg |
| Paracetamol | 500 mg |
| Serratiopeptidase | 15 mg |
Additional Information:
Additional Information:
Additional Information:
Product Details:
| Usage | Commercial, Hospital |
| Product Type | Finished Product |
| Packaging Size | 30 ml |
| Each 5 ml Suspension Contains: | |
| Albendazole I.P. | 200 mg. |
Additional Information:
Product Details:
| Packaging Size | sachet, pouch |
| Usage | Personal, Hospital |
Additional Information:
Additional Information:
Product Details:
| Dosage Form (If Applicable) | Syrup |
| Usage | Hospital, Commercial |
| Product Type | Finished Product |
Additional Information:
Product Details:
| Dosage Form (If Applicable) | Capsules, Tablets |
| Usage | Hospital, Clinical |
| Product Type | Finished Product |
Product Details:
| Packaging Type | Sachet , Bag |
| Usage | Commerical |
Product Details:
| Packaging Type | Bags, Pouches, |
| Usage | Clinical, Hospital |